BioSpace News Archive

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company’s Type II Variation Marketing

- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic - Sanofi to manufacture up to 200 million doses of Moderna’s vaccine in the U.S. starting in September 2021

Soligenix, Inc. products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim , MD, Medical Director, Dermatology Clinic, delivered a presentation at the American Academy of Dermatology (AAD) Association Virtual Meeting Experience, held April 23-25, 2021.

Catamaran Bio, Inc. , a biotechnology company developing allogeneic CAR-NK cell therapies to treat patients with significant unmet medical need, today announced the appointment of Scott Holmes, MS, MBA, as Chief Financial Officer. Mr. Holmes has 20 years of experience in finance, strategy, and operations, including roles as Chief Financial Officer of multiple biotechnology companies where he led high-value financings

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2021 financial results.

Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that two abstracts related to Progenity’s ingestible drug delivery technologies for the treatment of gastrointestinal disorders have been accepted for presentation at Digestive Disease Week ® (DDW). The DDW Virtual Meeting, taking place May 21-23, 2021, is the world’s prem

Veterinary physiotherapy involves assessment and treatment of musculoskeletal and neurological conditions in animals.

The biopharmaceuticals industry is currently following a new type of technological advancement, commonly known as single-use technology, which is essentially all forms of devices and technologies that are specifically designed for single-use purposes or for disposal on use.

Intracranial pressure (ICP) monitoring is vital for several neurosurgical and neurological patients. The gold standard for monitoring ICP, however, is via an invasive procedure, leading to the position of an intraventricular catheter, which is associated with numerous risks.

There has been augmented focus on personalized medicines and drug discovery utilizing in vitro methods.